Rhythm Pharmaceuticals, Inc. RYTM Remainder of Fiscal Year 2025

Remainder of Fiscal Year 2025 at other companies

Mirum Pharmaceuticals, Inc.MIRM

——

BridgeBio PharmaBBIO

——

MedtronicMDT

——

Other financials

Income statement

See full

Revenue$60.1M+83.8%

Gross profit$53.0M+82.3%

Operating income-$52.4M-11.4%

Net income-$55.6M-12.4%

EPS (diluted)-$0.83-2.5%

Balance sheet

See full

Cash & equivalents$62.1M-41.4%

Total debt$112.3M-1.1%

Total equity$122.9M+549%

Total assets$442.3M+14.4%

Cash flow

See full

Operating cash flow-$44.2M-9.5%

CapEx$238.3K—

Free cash flow-$29.2M-2.4%

Valuation

See full

Market cap$6.64B+77.3%

Enterprise value$6.69B+78.4%

P/S30.6×+3.2×

Profitability

See full

Gross margin89.4%-0.2pp

Operating margin-90.9%-19.8pp

Net margin-93.3%-18.2pp

FCF margin-61.5%-14.1pp

Returns & leverage

See full

Return on equity-285.8%-68.9pp

Debt / equity0.9×-5.1×

Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s remainder of fiscal year 2025.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s remainder of fiscal year 2025?: Rhythm Pharmaceuticals, Inc. (RYTM) reported remainder of fiscal year 2025 of $641K in Q1 2026.